Baxter ($BAX) Supply Chain Failures, Misleading Forecasts, and CFO Resignation Case

N.D. Illinois

Court

1:25-cv-12672

Case number

02/23/2025

Class period Start

07/30/2025

Class period End

12/15/2025

Lead Plaintiff motion deadline

$BAX investors filed a claim against Baxter International for concealing operational disruptions tied to its supply chain and inventory systems, issuing false financial guidance, and misleading the market about its cost-cutting progress and margin recovery.
After Baxter paused shipments and installations of the Novum LVP and admitted it could not commit to a restart timeline, $BAX fell 22.4% on July 30, 2025, to July 31.
$BAX investors can join this case to be notified about potential recovery.
Case Details:

Between February 8, 2024, and July 30, 2025, Baxter promoted its new Novum LVP (large-volume pump) as a safe and effective infusion technology for hospital and clinical use. Executives emphasized the product’s innovation and rollout timeline, and reassured investors about its regulatory compliance and commercial momentum. No public disclosures indicated that the device carried risks of inaccurate dosing or patient harm.

However, concerns about Novum LVP began to surface on April 7, 2025, when a Missouri news outlet published a whistleblower report citing serious safety failures. According to the report, the Novum pumps were inaccurately infusing fluids, posing risks of underdosing or overdosing patients. This triggered alarm among clinicians and raised questions about Baxter’s internal quality controls.

On April 24, 2025, Baxter issued a warning letter to customers acknowledging underinfusion risks, but downplayed the severity—disclosing just one reported serious injury. Then, on July 14, 2025, Baxter issued a second letter expanding the warning to include overinfusion risks and, for the first time, revealed it had received 79 reports of serious injuries and two reports of patient deaths tied to the Novum LVP. Despite the escalating number of incidents, Baxter continued to market and distribute the product through mid-July.

The situation escalated further on July 31, 2025, when Baxter publicly announced it would “voluntarily and temporarily pause shipments and planned installations” of the Novum LVP. The company also disclosed that it was “unable to currently commit to an exact timing” for resuming shipments, signaling major product and regulatory uncertainty. Investors were stunned by the reversal and by the scope of safety issues previously undisclosed.

Following the news, $BAX stock fell 22.4% in one day, dropping from $28.03 on July 30 to $21.76 on July 31, reflecting widespread concern about product liability, regulatory exposure, and reputational damage.

Based on these events, $BAX investors filed a claim against Baxter, alleging the company:
It concealed serious safety risks and internal injury reports tied to the Novum LVP.
It misled investors about the reliability, readiness, and regulatory standing of its infusion pump rollout.
It failed to disclose the full extent of patient harm and quality control issues until shipment was halted.
Investors argue Baxter misrepresented the safety of a flagship medical product, exposing the company to reputational, legal, and financial harm once the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Appointment

Alleged Offence

Misleading Statements,

Financial Misrepresentation,

Failure to Disclose

Suspected Party

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

07/31/2025

Filing date

10/16/2025

Lead Plaintiff Deadline

12/15/2025

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.